Mycobacterium ulcerans Disease: Experience with Primary Oral Medical Therapy in an Australian Cohort

PLoS Neglected Tropical Diseases

Volumn 7, Issue 7, 2013, Pages

  Friedman, N Deborah ^a   Athan, Eugene ^a   Hughes, Andrew J ^a   Khajehnoori, Masoomeh ^b   McDonald, Anthony ^a   Callan, Peter ^a   Rahdon, Richard ^a   O'Brien, Daniel P ^a,c,d  

^a BARWON HEALTH   (Australia)

^b Deakin University Medical School   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; MOXIFLOXACIN; PREDNISOLONE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BURULI ULCER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; MALE; MYCOBACTERIUM ULCERANS; OBSERVATIONAL STUDY; PARADOXICAL DRUG REACTION; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; TREATMENT RESPONSE; ULCER; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

EID: 84880824119     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002315     Document Type: Article

References (20)

1. van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K, (1999) Mycobacterium ulcerans infection. Lancet 354: 1013-1018.
2. Boyd SC, Athan E, Friedman ND, Hughes A, Walton A, et al. (2012) Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust 196: 341-344.
3. Sizaire V, Nackers F, Comte E, Portaels F, (2006) Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 6: 288-296.
4. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
5. O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, et al. (2012) Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 6: e1473.
6. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664-672.
7. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, et al. (2011) Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 52: 94-96.
8. Friedman ND, McDonald AH, Robson ME, O'Brien DP, (2012) Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLoS Negl Trop Dis 6: e1767 DOI:10.1371/journal.pntd.0001767.
9. Quek TY, Henry MJ, Pasco JA, O'Brien DP, Johnson PD, et al. (2007) Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust 187: 561-563.
10. O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, et al. (2007) Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 186: 58-61.
11. O'Brien DP, Robson ME, Callan PP, McDonald AH, (2009) "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 191: 564-6.
12. World Health Orgainisation (2012) Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. In: Organisation WH, editor. Geneva, Switzerland.
13. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182-3186.
14. Stinear TP, Hong H, Frigui W, Pryor MJ, Brosch R, et al. (2005) Common Evolutionary Origin for the Unstable Virulence Plasmid pMUM Found in Geographically Diverse Strains of Mycobacterium ulcerans. J Bacteriol 187: 1668-1676.
15. Chemlal K, De Ridder PA, Fonteyne W, Meyers M, Swings J, et al. (2001) The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas. Am J Trop Med Hyg 64: 270-273.
16. Stinear TP, Jenkin GA, Johnson PDR, Davies JK, (2000) Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 182: 6322-6330.
17. Doig KD, Holt KE, Fyfe JAM, Lavender CJ, Eddvani M, et al. (2012) On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC genomics 13: 258.
18. Nienhuis WA, Stienstra Y, Abass M, Tuah W, Thompson WA, et al. (2012) Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans Infection. Clin Infect Dis 54: 519-26.
19. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, et al. (2002) Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis 6: 497-502.
20. Schaaf HS, Willemse M, Cilliers K, Labadarios D, Maritz JS, et al. (2009) Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 7: 19.